Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CET
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
12/05 CYTOKINETICS INC : Change in Directors or Principal Officers (form 8-K)
12/03 CYTOKINETICS : Announces Presentations at the International Symposium on ALS/MND
12/02 Cytokinetics Announces Presentations at the International Symposium on ALS/MN..
12/02 CYTOKINETICS : Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omeca..
12/01 Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omec..
12/01 CYTOKINETICS INC : Other Events (form 8-K)
12/01 CYTOKINETICS : The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamt..
12/01 The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil ..
11/23 CYTOKINETICS INC : Change in Directors or Principal Officers (form 8-K)
11/22 Cytokinetics to Participate in Upcoming Investor Conferences
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2016 84,9 M
EBIT 2016 -5,02 M
Net income 2016 -6,24 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 5,39x
Capi. / Sales 2017 12,1x
Capitalization 458 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,8 $
Spread / Average Target 57%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.458
AMGEN, INC.-10.50%107 951
GILEAD SCIENCES, INC.-28.38%95 476
CELGENE CORPORATION-1.98%91 001
REGENERON PHARMACEUTIC..-32.04%38 913
ACTELION LTD45.20%21 783
More Results